Current Realities of Make vs. Buy For Advanced Therapies in Manufacturing

This panel of leading industry experts will discuss key considerations and experiences related to the Make vs. Buy decision from a variety of perspectives. Speakers will debate whether those considerations are unique to today’s environment and how they might be different in the future. How have the supply chain disruptions post-pandemic affected production? Has prioritization of vaccine manufacturing been a benefit or a challenge to other therapeutic production? What is the impact of de-risking innovative technologies to improve biologics manufacturing in the future? This session will solicit significant audience input to shape the discussion.